How precision oncology is improving care for patients with early-stage cancer
For patients with early-stage cancer, precision oncology can be used to tailor treatment based on a patient’s risk of recurrence by also looking at circulating tumor DNA (ctDNA) levels. Assessing ctDNA is in a patient’s blood after surgery helps doctors consider whether to deploy additional treatment options or tighter surveillance. This allows doctors to be more precise in personalizing the management of their patients with early-stage cancer.
Click the button below to find out more about testing for early-stage cancer.